News for VRNA Stock

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade Verona Pharma Announces June 2025 Investor Conference Participation Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025 Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update Xeris Announces Changes to Its Board of Directors Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Verona Pharma Announces March 2025 Investor Conference Participation Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights Verona Pharma Announces December 2024 Investor Conference Participation Verona Pharma to Present at Jefferies London Healthcare Conference Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024 Ritedose is Proud to Partner with Verona Pharma to Deliver First-In-Class COPD Drug, Ohtuvayre (ensifentrine)* Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024 Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update Verona Pharma to Present at 44th Annual Canaccord Growth Conference Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine) Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024 Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update Andrew Fisher Joins Verona Pharma as General Counsel Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update Michael Austwick Joins Verona Pharma as Non-Executive Director Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital Verona Pharma’s President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award Verona Pharma Announces November 2023 Investor Conference Participation Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update Verona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023 Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023 Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023 Christina Ackermann Joins Verona Pharma as Non-Executive Director Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update Verona Pharma to Present at 43rd Annual Canaccord Growth Conference Verona Pharma to Report Second Quarter 2023 Financial Results and Provide Corporate Update Verona Pharma Announces Publication of Phase 3 ENHANCE Data in the American Journal of Respiratory and Critical Care Medicine Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD Verona Pharma to Present at Jefferies Healthcare Conference Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023 Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD Nuance Pharma Announces Dosing of First Patient in ENHANCE - China Phase III Trial for Chronic Obstructive Pulmonary Disease ("COPD") Extremely Robust Acute Respiratory Distress Syndrome Pipeline Featuring 100+ Companies Expected to Change the Pace of the ARDS Treatment | DelveInsight Notice of Annual general meeting in Swedish Orphan Biovitrum AB (publ) COPD and Asthma Devices Global Market Report 2023: Sector to Reach $60.4 Billion by 2028 at a 5.66% CAGR Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Propulsion of Asthma Pipeline as Novel and Extensive 95+ Therapies Likely to Enter in the Treatment Domain | DelveInsight The Worldwide Inhalable Drugs Industry is Expected to Reach $49.47 Billion by 2027: Players Include AptarGroup, AstraZeneca, Cipla, GEA and GSK Ligand Reports Fourth Quarter and Full Year 2022 Financial Results Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update The Global Therapeutic Respiratory Devices Market to Surge at a Significant CAGR of ~9% by 2027 | DelveInsight Global COPD and Asthma Devices Market 2022 - 2027: Players Include Adherium, Aristopharma, AstraZeneca, Baxter International and Boehringer Ingelheim International Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-1 Trial of Nebulized Ensifentrine for COPD Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update Ligand Reports Third Quarter 2022 Financial Results Verona Pharma Announces November 2022 Investor Conference Participation Verona Pharma to Report Third Quarter 2022 Financial Results and Provide Corporate Update Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups in Phase 3 ENHANCE-2 Trial for COPD Verona Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference Verona Pharma strengthens commercialization leadership team Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional ADSs Verona Pharma plc Announces Pricing of Upsized Underwritten Public Offering Verona Pharma plc Announces Proposed Underwritten Public Offering Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-2 Trial of Nebulized Ensifentrine for COPD Verona Pharma to Report Second Quarter 2022 Financial Results and Provide Corporate Update Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD Verona Pharma to Host KOL Event on June 16, 2022 Verona Pharma to Present at Jefferies Healthcare Conference Verona Pharma to Present Successful TQT Analysis Demonstrating No Clinically Relevant Effect on Cardiac Conduction at the American Thoracic Society 2022 Verona Pharma Announces May 2022 Investor Conference Participation Verona Pharma Reports First Quarter 2022 Financial Results and Provides Corporate Update Verona Pharma to Report First Quarter 2022 Financial Results and Provide Corporate Update James Brady Joins Verona Pharma as Non-Executive Director Verona Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Verona Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update Ligand Reports Fourth Quarter and Full Year 2021 Financial Results Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference Verona Pharma Reports TQT Study Successfully Demonstrated No Clinically Relevant Effect on Cardiac Conduction Verona Pharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update Verona Pharma Announces November 2021 Investor Conference Participation Verona Pharma to Report Third Quarter 2021 Financial Results and Provide Corporate Update Verona Pharma to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021 Verona Pharma Presents Pharmacokinetic Data with Ensifentrine at the European Respiratory Society International Congress 2021 Verona Pharma to Present at H.C. Wainwright 23rd Annual Global Investment Conference Verona Pharma Reports Second Quarter 2021 Financial Results and Provides Corporate Update Verona Pharma Announces August 2021 Virtual Investor Conference Participation Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China Verona Pharma to Present at Jefferies Virtual Healthcare Conference Verona Pharma to Present Expanded Analysis of Phase 2b COPD Data with Ensifentrine at the American Thoracic Society 2021 International Conference Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update Verona Pharma Announces Publication of Phase 2b Dose-Ranging COPD Data in the International Journal of Chronic Obstructive Pulmonary Disease Verona Pharma Reports Results of Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19 Verona Pharma to Report First Quarter 2021 Financial Results and Provide Corporate Update Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020 Lisa Deschamps Joins Verona Pharma as Non-Executive Director Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference Verona Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update Verona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD Verona Pharma Announces Publication of Phase 2b COPD Symptom Data in the International Journal of Chronic Obstructive Pulmonary Disease Verona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19 Verona Pharma to Present at H.C. Wainwright 22nd Annual Global Virtual Investment Conference Verona Pharma plc: Grant of RADSUs and PDMR Dealings Verona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2020 Verona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPD Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020